Citations

Clear

6274 citation(s) found for "To, Andrew".

Associations Between Glycemic Traits and Colorectal Cancer: A Mendelian Randomization Analysis
Murphy, Neil , Song, Mingyang , Papadimitriou, Nikos , Carreras‐Torres, Robert , Langenberg, Claudia , Martin, Richard M. , Tsilidis, Konstantinos K. , Barroso, Inês , Chen, Ji , Vincent, Emma E. , Cotterchio, Michelle , Gruber, Stephen B. , Pai, Rish K. , Perez‐Cornago, Aurora , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Vodička, Pavel , Wu, Anna H. , Peters, Ulrike , Gunter, Marc J. , Frayling, Timothy M , Bull, Caroline J , Vincent, Emma E , Gruber, Stephen B , Pai, R K , Perez-Cornago, Aurora , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Wolk, Alicja , Chan, Andrew T , Gunter, Marc J , Murphy, Neil , Martin, Richard M , Song, Mingyang , Carreras-Torres, Robert , Tsilidis, Konstantinos K , Papadimitriou, Nikos , Vodicka, Pavel , Bull, Caroline J. , Newcomb, Polly A. , Wolk, Alicja , Chan, Andrew T.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 14, 2022 | Volume: 114 | Issue: 5 | Pages: 740-752

10.1093/jnci/djac011 | PMID 35048991 Get It

Abstract Background Glycemic traits—such as hyperinsulinemia, hyperglycemia, and type 2 diabetes—have been associated with higher colorectal cancer risk in observational studies; however, causality of these associations is uncertain. We used Mendelian randomization (MR) to estimate the causal effects of fasting insulin, 2-hour glucose, fasting glucose, glycated hemoglobin (HbA1c), and type 2 diabetes with colorectal cancer. Methods Genome-wide association study summary data were used to identify genetic variants associated with circulating levels of fasting insulin (n = 34), 2-hour glucose (n = 13), fasting glucose (n = 70), HbA1c (n = 221), and type 2 diabetes (n = 268). Using 2-sample MR, we examined these variants in relation to colorectal cancer risk (48 214 case patient and 64 159 control patients). Results In inverse-variance models, higher fasting insulin levels increased colorectal cancer risk (odds ratio [OR] per 1-SD = 1.65, 95% confidence interval [CI] = 1.15 to 2.36). We found no evidence of any effect of 2-hour glucose (OR per 1-SD = 1.02, 95% CI = 0.86 to 1.21) or fasting glucose (OR per 1-SD = 1.04, 95% CI = 0.88 to 1.23) concentrations on colorectal cancer risk. Genetic liability to type 2 diabetes (OR per 1-unit increase in log odds = 1.04, 95% CI = 1.01 to 1.07) and higher HbA1c levels (OR per 1-SD = 1.09, 95% CI = 1.00 to 1.19) increased colorectal cancer risk, although these findings may have been biased by pleiotropy. Higher HbA1c concentrations increased rectal cancer risk in men (OR per 1-SD = 1.21, 95% CI = 1.05 to 1.40), but not in women. Conclusions Our results support a causal effect of higher fasting insulin, but not glucose traits or type 2 diabetes, on increased colorectal cancer risk. This suggests that pharmacological or lifestyle interventions that lower circulating insulin levels may be beneficial in preventing colorectal tumorigenesis.
Solid Organ Transplantation From SARS-CoV-2–infected Donors to Uninfected Recipients: A Single-center Experience
Jayasekera, Channa R., Vikram, Holenarasipur R., Rifat, Zeeshan, Wagler, Josiah, Okubo, Keita, Braaksma, Brandon R., Harbell, Jack W., Jadlowiec, Caroline C., Katariya, Nitin N., Mathur, Amit K., Moss, Adyr, Reddy, K. Sudhakar, Singer, Andrew, Orenstein, Robert, Saling, Christopher F., Seville, Maria T., Mour, Girish K., Vargas, Hugo E., Byrne, Thomas J., Hewitt, Winston R., Aqel, Bashar A., Vargas, Hugo E. , Vikram, Holenarasipur R. , Katariya, Nitin , Vikram, Holenarasipur R. , Vargas, Hugo E , Katariya, Nitin N , Jayasekera, Channa R., Rifat, Zeeshan, Wagler, Josiah, Okubo, Keita, Braaksma, Brandon R., Harbell, Jack W., Jadlowiec, Caroline C., Mathur, Amit K., Moss, Adyr, Reddy, K. Sudhakar, Singer, Andrew, Orenstein, Robert, Saling, Christopher F., Seville, Maria T., Mour, Girish K., Byrne, Thomas J., Hewitt, Winston R., Aqel, Bashar A., Okubo, Keita

Mayo Clinic

Transplantation Direct | January 13, 2022 | Volume: 8 | Issue: 2 | Pages: e1286

10.1097/txd.0000000000001286 | PMID 35047665 Get It

Background. The risk of donor-derived severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in solid organ (heart, lung, liver, kidney, pancreas, and intestine) transplant recipients is poorly understood. Since hematogenous transmission of SARS-CoV-2 has not been documented to date, nonlung solid organs might be suitable for transplantation since they likely portend a low risk of viral transmission. Methods. Abdominal solid organs from SARS-CoV-2–infected donors were transplanted into uninfected recipients. Results. Between April 18, 2021, and October 30, 2021, we performed transplants of 2 livers, 1 simultaneous liver and kidney, 1 kidney, and 1 simultaneous kidney and pancreas from SARS-CoV-2–infected donors into 5 uninfected recipients. None of the recipients developed SARS-CoV-2 infection or coronavirus disease 2019, and when tested, allograft biopsies showed no evidence of SARS-CoV-2 RNA. Conclusions. Transplanting nonlung organs from SARS-CoV-2–infected donors into uninfected recipients demonstrated no evidence of virus transmission.
Death With Function and Graft Failure After Kidney Transplantation: Risk Factors at Baseline Suggest New Approaches to Management
Merzkani, Massini A., Bentall, Andrew J., Smith, Byron H., Lopez, Xiomara Benavides, D’Costa, Matthew R., Park, Walter D., Kremers, Walter K., Issa, Naim, Rule, Andrew D., Chakkera, Harini, Reddy, Kunam, Khamash, Hasan, Wadei, Hani M., Mai, Martin, Alexander, Mariam P., Amer, Hatem, Kukla, Aleksandra, Ters, Mireille El, Schinstock, Carrie A., Gandhi, Manish J., Heilman, Raymond, Stegall, Mark D., Kremers, Walter K. , Chakkera, Harini A. , Wadei, Hani M. , D’Costa, Matthew R. , Benavides Lopez, Xiomara, El Ters, Mireille, D'Costa, Matthew , Chakkera, Harini A , Wadei, Hani M , Kremers, Walter K , Merzkani, Massini A., Bentall, Andrew J., Smith, Byron H., Lopez, Xiomara Benavides, Park, Walter D., Issa, Naim, Rule, Andrew D., Reddy, Kunam, Khamash, Hasan, Mai, Martin, Alexander, Mariam P., Amer, Hatem, Kukla, Aleksandra, Ters, Mireille El, Schinstock, Carrie A., Gandhi, Manish J., Heilman, Raymond, Stegall, Mark D.

Mayo Clinic

Transplantation Direct | January 13, 2022 | Volume: 8 | Issue: 2 | Pages: e1273

10.1097/txd.0000000000001273 | PMID 35047660 Get It

Background. Improving both patient and graft survival after kidney transplantation are major unmet needs. The goal of this study was to assess risk factors for specific causes of graft loss to determine to what extent patients who develop either death with a functioning graft (DWFG) or graft failure (GF) have similar baseline risk factors for graft loss. Methods. We retrospectively studied all solitary renal transplants performed between January 1, 2006, and December 31, 2018, at 3 centers and determined the specific causes of DWFG and GF. We examined outcomes in different subgroups using competing risk estimates and cause-specific Cox models. Results. Of the 5752 kidney transplants, graft loss occurred in 21.6% (1244) patients, including 12.0% (691) DWFG and 9.6% (553) GF. DWFG was most commonly due to malignancy (20.0%), infection (19.7%), cardiac disease (12.6%) with risk factors of older age and pretransplant dialysis, and diabetes as the cause of renal failure. For GF, alloimmunity (38.7%), glomerular diseases (18.6%), and tubular injury (13.9%) were the major causes. Competing risk incidence models identified diabetes and older recipients with higher rates of both DWFG and nonalloimmune GF. Conclusions. These data suggest that at baseline, 2 distinct populations can be identified who are at high risk for renal allograft loss: a younger, nondiabetic patient group who develops GF due to alloimmunity and an older, more commonly diabetic population who develops DWFG and GF due to a mixture of causes—many nonalloimmune. Individualized management is needed to improve long-term renal allograft survival in the latter group.
Targeting Protein Arginine Methyltransferase 5 Suppresses Radiation-induced Neuroendocrine Differentiation and Sensitizes Prostate Cancer Cells to Radiation
Owens, Jake L. , Beketova, Elena , Liu, Sheng, Shen, Qi, Pawar, Jogendra Singh , Asberry, Andrew M. , Yang, Jie, Deng, Xuehong, Elzey, Bennett D., Ratliff, Timothy L. , Cheng, Liang , Choo, Richard, Citrin, Deborah E., Polascik, Thomas J., Wang, Bangchen, Huang, Jiaoti, Li, Chenglong, Hu, Chang-Deng, Citrin, Deborah E. , Wang, Bangchen , Shen, Qi , Wan, Jun , Cheng, Liang , Wang, Bangchen , Owens, Jake L. , Beketova, Elena , Liu, Sheng, Shen, Qi, Pawar, Jogendra Singh , Asberry, Andrew M. , Yang, Jie, Deng, Xuehong, Elzey, Bennett D., Ratliff, Timothy L. , Choo, Richard, Polascik, Thomas J., Wang, Bangchen, Huang, Jiaoti, Li, Chenglong, Hu, Chang-Deng

Mayo Clinic

Molecular Cancer Therapeutics | January 13, 2022 | Volume: 21 | Issue: 3 | Pages: 448-459

10.1158/1535-7163.mct-21-0103 | PMID 35027481 Get It

Abstract Prostate cancer remains the second leading cause of cancer death among American men. Radiotherapy is a potentially curative treatment for localized prostate cancer, and failure to control localized disease contributes to the majority of prostate cancer deaths. Neuroendocrine differentiation (NED) in prostate cancer, a process by which prostate adenocarcinoma cells transdifferentiate into neuroendocrine-like (NE-like) cells, is an emerging mechanism of resistance to cancer therapies and contributes to disease progression. NED also occurs in response to treatment to promote the development of treatment-induced neuroendocrine prostate cancer (NEPC), a highly aggressive and terminal stage disease. We previously demonstrated that by mimicking clinical radiotherapy protocol, fractionated ionizing radiation (FIR) induces prostate cancer cells to undergo NED in vitro and in vivo. Here, we performed transcriptomic analysis and confirmed that FIR-induced NE-like cells share some features of clinical NEPC, suggesting that FIR-induced NED represents a clinically relevant model. Furthermore, we demonstrated that protein arginine methyltransferase 5 (PRMT5), a master epigenetic regulator of the DNA damage response and a putative oncogene in prostate cancer, along with its cofactors pICln and MEP50, mediate FIR-induced NED. Knockdown of PRMT5, pICln, or MEP50 during FIR-induced NED and sensitized prostate cancer cells to radiation. Significantly, PRMT5 knockdown in prostate cancer xenograft tumors in mice during FIR prevented NED, enhanced tumor killing, significantly reduced and delayed tumor recurrence, and prolonged overall survival. Collectively, our results demonstrate that PRMT5 promotes FIR-induced NED and suggests that targeting PRMT5 may be a novel and effective radiosensitization approach for prostate cancer radiotherapy.
Accounting for EGFR Mutations in Epidemiologic Analyses of Non–Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data
Schmid, Sabine , Jiang, Mei , Brown, M. Catherine , Fares, Aline Fusco , García-Pardo, Miguel , Soriano, Joelle , Dong, Mei , Thomas, Sera , Kohno, Takashi , Leal, Letícia Ferro , Diao, Nancy , Xie, Juntao , Wang, Zhichao , Заридзе, Давид , Świątkowska, Beata , Savić, Milan , Wenzlaff, Angela S. , Harris, Curtis C. , Caporaso, Neil E. , Ma, Hongxia , Fernández‐Tardón, Guillermo , Barnett, Matthew J, Goodman, Gary E. , Davies, Michael P.A. , Pérez‐Ríos, Mónica , Taylor, Fiona, Schoettker, Ben, Brenner, Hermann , Andrew, Angeline S. , Cox, Angela , Field, John K. , Wang, Ying , Chen, Chu , Tardón, Adonina , Shete, Sanjay , Shen, Hongbing , Landi, Maria Teresa , Schwartz, Ann G. , Qi, Lihong , Brennan, Paul , Reis, Rui Manuel , Liu, Geoffrey , Świątkowska, Beata , Mates, Dana , Wenzlaff, Angela S , Fernandez-Tardon, Guillermo , Barnett, Matthew J , Davies, Michael P A , Duell, Eric J , Brenner, Hermann , Cox, Angela , Ruano-Ravina, Alberto , Field, John K , Tardón, Adonina , Schabath, Matthew B , Schwartz, Ann G , Sakoda, Lori C , Brennan, Paul , Yang, Ping , Christiani, David C. , Reis, Rui Manuel , Hung, Rayjean J , Liu, Geoffrey , Shen, Hongbing , Dong, Mei , Holcátová, Ivana , Lissowska, Jolanta , Mateș, Dana , Duell, Eric J. , Marchand, Loı̈c Le , Schabath, Matthew B. , Ryan, Bríd M. , Sakoda, Lori C. , Yang, Ping , Zhang, Jie , Shiraishi, Kouya , Hung, Rayjean J. , Xu, Wei

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 13, 2022 | Volume: 31 | Issue: 3 | Pages: 679-687

10.1158/1055-9965.epi-21-0747 | PMID 35027437 Get It

Abstract Background: Somatic EGFR mutations define a subset of non–small cell lung cancers (NSCLC) that have clinical impact on NSCLC risk and outcome. However, EGFR-mutation-status is often missing in epidemiologic datasets. We developed and tested pragmatic approaches to account for EGFR-mutation-status based on variables commonly included in epidemiologic datasets and evaluated the clinical utility of these approaches. Methods: Through analysis of the International Lung Cancer Consortium (ILCCO) epidemiologic datasets, we developed a regression model for EGFR-status; we then applied a clinical-restriction approach using the optimal cut-point, and a second epidemiologic, multiple imputation approach to ILCCO survival analyses that did and did not account for EGFR-status. Results: Of 35,356 ILCCO patients with NSCLC, EGFR-mutation-status was available in 4,231 patients. A model regressing known EGFR-mutation-status on clinical and demographic variables achieved a concordance index of 0.75 (95% CI, 0.74–0.77) in the training and 0.77 (95% CI, 0.74–0.79) in the testing dataset. At an optimal cut-point of probability-score = 0.335, sensitivity = 69% and specificity = 72.5% for determining EGFR-wildtype status. In both restriction-based and imputation-based regression analyses of the individual roles of BMI on overall survival of patients with NSCLC, similar results were observed between overall and EGFR-mutation-negative cohort analyses of patients of all ancestries. However, our approach identified some differences: EGFR-mutated Asian patients did not incur a survival benefit from being obese, as observed in EGFR-wildtype Asian patients. Conclusions: We introduce a pragmatic method to evaluate the potential impact of EGFR-status on epidemiological analyses of NSCLC. Impact: The proposed method is generalizable in the common occurrence in which EGFR-status data are missing.
Prevalence and Amounts of Common Ingredients Found in Energy Drinks and Shots
Jagim, Andrew R. , Barakat, Abdelrahman , Erickson, Jacob L. , Carvalho, Victoria , Khurelbaatar, Chinguun, Camic, Clayton L., Kerksick, Chad M. , Harty, Patrick S , Barakat, Abdelrahman R, Jagim, Andrew R , Kerksick, Chad M , Harty, Patrick S.

Mayo Clinic

Nutrients | January 12, 2022 | Volume: 14 | Issue: 2 | Pages: 314

10.3390/nu14020314 | PMID 35057494 Get It

Background: Energy drinks are one of the most popular packaged beverage products consumed within the United States (US). Energy drinks are considered a functional beverage, a category that also includes sports drinks and nutraceutical beverages. Purpose: The focus of the current study was to examine the nutrition fact panels of the top selling commercially available energy drink and energy shot products within the US to characterize common ingredient profiles to help establish a standard definition and ingredient profile of energy drinks and energy shots for consumers, health care practitioners, and researchers. Methods: The top 75 commercially available energy drinks and shots were identified and compiled from multiple commercial retail websites as of September 2021. For the purpose of this study, an energy drink must have met the following criteria: (A) marketed as an energy drink; (B) purported to improve energy, focus, or alertness; (C) not sold as a dietary supplement (no supplement fact panels); (D) manufactured as a pre-packaged and ready-to-drink beverage; and (E) contains at least three of (1) caffeine, (2) B-vitamins, (3) sugar, (4) taurine, (5) creatine, (6) quercetin, (7) guarana, (8) ginseng, (9) coenzyme Q10, or (10) branched chain amino acids. Energy shots must have met similar criteria to be included: (A) marketed as an energy shot; (B) purported to improve energy, focus, or alertness; (C) sold as a dietary supplement; (D) manufactured as a pre-packaged beverage with a small volume (<3.5 mL); and (E) contains at least three of the ingredients stated above. Results: Twenty energy shots and fifty-five energy drinks were included in this analysis. The number of ingredients per product (mean ± SD) was 18.2 ± 5.7, with 15 products containing proprietary blends with undisclosed ingredient amounts. The relative prevalence and average amounts of the top ingredients were as follows: caffeine (100%; 174.4 ± 81.1 mg), vitamin B6 (72%; 366.9 ± 648.1 percent daily value (%DV)), vitamin B3 (67%; 121.44 ± 69.9% DV), vitamin B12 (67%; 5244.5 ± 10,474.6% DV), vitamin B5 (37.3%; 113.6 ± 76.6% DV), and taurine (37.3%; amounts undisclosed). Conclusions: Our findings suggest a high prevalence of caffeine and B-vitamins in these energy products, with many of the formulations containing well above the recommended daily value of B-vitamins.
Sport-Related Concussion Preceding Adrenal Insufficiency and Hypopituitarism
Northam, Weston T. , Carneiro, Kevin A., Alexander, Andrew

Mayo Clinic

Current Sports Medicine Reports | January 12, 2022 | Volume: 21 | Issue: 1 | Pages: 15-17

10.1249/jsr.0000000000000926 | PMID 35018894 Get It

Abstract A 49-year-old woman with a history of daily inhaled corticosteroid use for asthma presented to a concussion clinic 7 wk after sport-related head injury with headache, visual blurring, dizziness, nausea, fatigue, polydipsia, and polyuria. Examination revealed difficulty with vestibulo-occulomotor testing due to nausea and visual straining. Cranial CT/MR imaging was unremarkable. Laboratory testing revealed critically low serum cortisol, hypernatremia, and urine studies suggesting diabetes insipidus. The patient was referred to the emergency department. Intravenous fluid resuscitation, corticosteroids, and desmopressin led to significant symptomatic relief. She was maintained on oral hydrocortisone after cosyntropin test revealed adrenal insufficiency. Her clinical picture suggested chronic subclinical adrenal suppression from inhaled corticosteroids, which was exacerbated by hypopituitarism possibly from concussion combined with diabetes insipidus. Adrenal insufficiency should be considered in athletes with history of corticosteroid use and endocrine-related symptoms after concussion, because this can create significant morbidity and can mimic traditional symptoms of concussion.
Hospital Frailty Risk Score and Healthcare Resource Utilization After Surgery for Primary Spinal Intradural/Cord Tumors
Elsamadicy, Aladine A. , Reeves, Benjamin C. , Pennington, Zach , Sarkozy, Margot , Hersh, Andrew M. , Sherman, Josiah , Goodwin, C. Rory , Kolb, Luis, Laurans, Maxwell , Lo, Sheng-Fu Larry , Sciubba, Daniel M. , Pennington, Zach , Hersh, Andrew , Goodwin, C Rory , Sciubba, Daniel , Koo, Andrew B. , Havlik, John, Shin, John H.

Mayo Clinic

Global Spine Journal | January 11, 2022 | Volume: 13 | Issue: 7 | Pages: 2074-2084

10.1177/21925682211069937 | PMID 35016582 Get It

Objective The Hospital Frailty Risk Score (HFRS) is a metric that measures frailty among patients in large national datasets using ICD-10 codes. While other metrics have been utilized to demonstrate the association between frailty and poor outcomes in spine oncology, none have examined the HFRS. The aim of this study was to investigate the impact of frailty using the HFRS on complications, length of stay, cost of admission, and discharge disposition in patients undergoing surgery for primary tumors of the spinal cord and meninges. Methods A retrospective cohort study was performed using the Nationwide Inpatient Sample database from 2016 to 2018. Adult patients undergoing surgery for primary tumors of the spinal cord and meninges were identified using ICD-10-CM codes. Patients were categorized into 2 cohorts based on HFRS score: Non-Frail (HFRS<5) and Frail (HFRS≥5). Patient characteristics, treatment, perioperative complications, LOS, discharge disposition, and cost of admission were assessed. Results Of the 5955 patients identified, 1260 (21.2%) were Frail. On average, the Frail cohort was nearly 8 years older ( P < .001) and experienced more postoperative complications ( P = .001). The Frail cohort experienced longer LOS ( P < .001), a higher rate of non-routine discharge ( P = .001), and a greater mean cost of admission ( P < .001). Frailty was found to be an independent predictor of extended LOS ( P < .001) and non-routine discharge ( P < .001). Conclusion Our study is the first to use the HFRS to assess the impact of frailty on patients with primary spinal tumors. We found that frailty was associated with prolonged LOS, non-routine discharge, and increased hospital costs.
Risk Stratification for Early-Onset Colorectal Cancer Using a Combination of Genetic and Environmental Risk Scores: An International Multi-Center Study
Archambault, Alexi , Jeon, Jihyoun , Thomas, Minta , Harrison, Tabitha A. , Bishop, D. Timothy , Brenner, Hermann , Casey, Graham , Chan, Andrew T. , Chang‐Claude, Jenny , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Gunter, Marc J. , Hoffmeister, Michael , Li, Li , Pai, Rish K. , Parfrey, Patrick S. , Rennert, Gad , Lee, Jeffrey K. , Slattery, Martha L. , Win, Aung Ko , Woods, Michael O. , Peterse, Elisabeth F.P. , Cao, Yin , Du, Mengmeng , Corley, Douglas A. , Peters, Ulrike , Song, Mingyang , Archambault, Alexi N , Harrison, Tabitha A , Bishop, D Timothy , Brenner, Hermann , Chan, Andrew T , Chang-Claude, Jenny , Figueiredo, Jane C , Gruber, Stephen B , Gunter, Marc J , Guo, Feng , Hoffmeister, Michael , Jenkins, Mark A , Marchand, Loïc Le , Moreno, Victor , Pai, R K , Rennert, Gad , Sakoda, Lori C , Song, Mingyang , Win, Aung K , Woods, Michael O , Murphy, Neil , Campbell, Peter T , Peterse, Elisabeth F P , Cao, Yin , Liang, Peter S , Hayes, Richard B , Jeon, Jihyoun , Lin, Yi , Jenkins, Mark A. , Keku, Temitope O , Marchand, Loı̈c Le , Moreno, Vı́ctor , Newcomb, Polly A. , Sakoda, Lori C. , Song, Mingyang , Murphy, Neil , Campbell, Peter T. , Su, Yu-Ru , Lansdorp‐Vogelaar, Iris , Zeleniuch‐Jacquotte, Anne , Liang, Peter S. , Hsu, Li , Hayes, Richard B.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | January 11, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djac003 | PMID 35026030 Get It

AbstractBackgroundThe incidence of colorectal cancer (CRC) among individuals aged younger than 50 years has been increasing. As screening guidelines lower the recommended age of screening initiation, concerns including the burden on screening capacity and costs have been recognized, suggesting that an individualized approach may be warranted. We developed risk prediction models for early-onset CRC that incorporate an environmental risk score (ERS), including 16 lifestyle and environmental factors, and a polygenic risk score (PRS) of 141 variants.MethodsRelying on risk score weights for ERS and PRS derived from studies of CRC at all ages, we evaluated risks for early-onset CRC in 3486 cases and 3890 controls aged younger than 50 years. Relative and absolute risks for early-onset CRC were assessed according to values of the ERS and PRS. The discriminatory performance of these scores was estimated using the covariate-adjusted area under the receiver operating characteristic curve.ResultsIncreasing values of ERS and PRS were associated with increasing relative risks for early-onset CRC (odds ratio per SD of ERS = 1.14, 95% confidence interval [CI] = 1.08 to 1.20; odds ratio per SD of PRS = 1.59, 95% CI = 1.51 to 1.68), both contributing to case-control discrimination (area under the curve = 0.631, 95% CI = 0.615 to 0.647). Based on absolute risks, we can expect 26 excess cases per 10 000 men and 21 per 10 000 women among those scoring at the 90th percentile for both risk scores.ConclusionsPersonal risk scores have the potential to identify individuals at differential relative and absolute risk for early-onset CRC. Improved discrimination may aid in targeted CRC screening of younger, high-risk individuals, potentially improving outcomes.
Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study
Domenighetti, Cloé , Sugier, Pierre‐Emmanuel, Sreelatha, Ashwin Ashok Kumar, Schulte, Claudia , Grover, Sandeep , Mohamed, Océane, Portugal, Berta, May, Patrick , Bobbili, Dheeraj Reddy , Radivojkov‐Blagojevic, Milena, Lichtner, Peter, Singleton, Andrew B., Hernandez, Dena G., Edsall, Connor, Mellick, George D., Zimprich, Alexander, Pirker, Walter, Rogaeva, Ekaterina, Lang, Anthony E., Koks, Sulev, Taba, Pille, Lesage, Suzanne, Brice, Alexis, Chartier‐Harlin, Marie‐Christine, Brockmann, Kathrin , Deutschländer, Angela B., Hadjigeorgiou, Georges M., Dardiotis, Efthimos, Stefanis, Leonidas, Simitsi, Athina Maria, Petrucci, Simona, Duga, Stefano, Straniero, Letizia, Zecchinelli, Anna, Pezzoli, Gianni, Brighina, Laura, Ferrarese, Carlo, Annesi, Grazia, Quattrone, Andrea, Gagliardi, Monica, Matsuo, Hirotaka, Kawamura, Yusuke, Hattori, Nobutaka, Nishioka, Kenya, Kim, Yun Joong, Kolber, Pierre, Warrenburg, Bart P.C. van de, Bloem, Bastiaan R., Aasly, Jan, Toft, Mathias , Pihlstrøm, Lasse, Guedes, Leonor Correia, Ferreira, Joaquim J., Bardien, Soraya , Carr, Jonathan, Tolosa, Eduardo, Ezquerra, Mario , Pastor, Pau, Diez‐Fairen, Monica, Wirdefeldt, Karin, Pedersen, Nancy L., Ran, Caroline, Belin, Andrea C., Puschmann, Andreas, Hellberg, Clara, Clarke, Carl E., Morrison, Karen E., Krainc, Dimitri, Burbulla, Lena F., Farrer, Matt J., Krüger, Rejko, Gasser, Thomas, Sharma, Manu , Elbaz, Alexis , Gasser, Thomas , Hattori, Nobutaka , Chartier‐Harlin, Marie‐Christine , Puschmann, Andreas , Guedes, Leonor Correia , Zimprich, Alexander , Clarke, Carl E , Mellick, George D. , Morrison, Karen , Krüger, Rejko , Ferrarese, Carlo , Kim, Yun Joong , Pezzoli, Gianni , Pástor, Pau , Ferreira, Joaquim J. , Portugal, Berta , Straniero, Letizia , Quattrone, Andrea , Matsuo, Hirotaka , Kawamura, Yusuke , Ran, Caroline , Bobbili, Dheeraj R , Corvol, Jean-Christophe , Mutez, Eugénie , Brockman, Kathrin , Valente, Enza Maria , Chung, Sun Ju , Toft, Mathias , Bardien, Soraya , Ezquerra, Mario , Tan, Manuela , Sharma, Manu , Elbaz, Alexis , Puschmann, Andreas , Schulte, Claudia , Grover, Sandeep , May, Patrick , Ferreira, Joaquim J , Zimprich, Alexander , Pastor, Pau , Koks, Sulev , Domenighetti, Cloé , Sugier, Pierre‐Emmanuel, Sreelatha, Ashwin Ashok Kumar, Mohamed, Océane, Radivojkov‐Blagojevic, Milena, Lichtner, Peter, Singleton, Andrew B., Hernandez, Dena G., Edsall, Connor, Pirker, Walter, Rogaeva, Ekaterina, Lang, Anthony E., Taba, Pille, Lesage, Suzanne, Brice, Alexis, Deutschländer, Angela B., Hadjigeorgiou, Georges M., Dardiotis, Efthimos, Stefanis, Leonidas, Simitsi, Athina Maria, Petrucci, Simona, Duga, Stefano, Zecchinelli, Anna, Brighina, Laura, Annesi, Grazia, Gagliardi, Monica, Matsuo, Hirotaka, Kawamura, Yusuke, Hattori, Nobutaka, Nishioka, Kenya, Kim, Yun Joong, Kolber, Pierre, Warrenburg, Bart P.C. van de, Bloem, Bastiaan R., Aasly, Jan, Pihlstrøm, Lasse, Guedes, Leonor Correia, Ferreira, Joaquim J., Carr, Jonathan, Tolosa, Eduardo, Diez‐Fairen, Monica, Wirdefeldt, Karin , Pedersen, Nancy L., Ran, Caroline, Belin, Andrea C., Hellberg, Clara, Clarke, Carl E., Morrison, Karen E., Krainc, Dimitri, Burbulla, Lena F., Farrer, Matt J.

Mayo Clinic

Movement Disorders | January 8, 2022 | Volume: 37 | Issue: 4 | Pages: 857-864

10.1002/mds.28902 | PMID 34997937 Get It

Abstract Background Previous prospective studies highlighted dairy intake as a risk factor for Parkinson's disease (PD), particularly in men. It is unclear whether this association is causal or explained by reverse causation or confounding. Objective The aim is to examine the association between genetically predicted dairy intake and PD using two‐sample Mendelian randomization (MR). Methods We genotyped a well‐established instrumental variable for dairy intake located in the lactase gene (rs4988235) within the Courage‐PD consortium (23 studies; 9823 patients and 8376 controls of European ancestry). Results Based on a dominant model, there was an association between genetic predisposition toward higher dairy intake and PD (odds ratio [OR] per one serving per day = 1.70, 95% confidence interval = 1.12–2.60, P = 0.013) that was restricted to men (OR = 2.50 [1.37–4.56], P = 0.003; P ‐difference with women = 0.029). Conclusions Using MR, our findings provide further support for a causal relationship between dairy intake and higher PD risk, not biased by confounding or reverse causation. Further studies are needed to elucidate the underlying mechanisms. © 2022 International Parkinson and Movement Disorder Society